A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) [Estudio de fase IIa prospectivo, multicéntrico, randomizado, doble ciego, y controlado con placebo para comparar la eficacia y seguridad del tratamiento con masitinib durante de 24 semanas frente a placebo en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC)]

Trial Profile

A prospective, multicentre, randomised, double-blind, placebo-controlled, phase 2a study to compare the efficacy and the safety of 24-week treatment with masitinib versus placebo in patients with severe Chronic Obstructive Pulmonary Disease (COPD) [Estudio de fase IIa prospectivo, multicéntrico, randomizado, doble ciego, y controlado con placebo para comparar la eficacia y seguridad del tratamiento con masitinib durante de 24 semanas frente a placebo en pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC)]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Masitinib (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jan 2016 Planned number of patients changed from 30 to 45 as reported by European Clinical Trials Database record.
    • 05 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top